Last reviewed · How we verify

NCT06675448

In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm

Recruiting now Last updated 3 December 2025
What this trial tests

trial testing MitraClip in Mitral Regurgitation in 50 participants. Currently enrolling.

Timeline
28 January 2021
Primary endpoint
10 September 2029
10 September 2030

Quick facts

Lead sponsorInova Health Care Services
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date28 January 2021
Primary completion10 September 2029
Estimated completion10 September 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Inova Health Care Services — full company profile →

Who can join

Adults 18 to 99, any sex, with Mitral Regurgitation or Valvular Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching goal of this research proposal is to study the feasibility and clinical impact of implementing an Inova system-wide heart failure treatment algorithm for patients with symptomatic heart failure due to reduced left ventricular ejection fraction (HFreF) and secondary MR Aim is to check the effectiveness of the IHFTA in identifying patients who are most likely to benefit from percutaneous transcatheter Mitraclip repair in real world

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MitraClip

Trials testing the same drug.

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

Other Inova Health Care Services trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06675448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing